Mountain View Pharmaceuticals, Inc.
Mountain View Pharmaceuticals, Inc., a prominent player in the pharmaceutical industry, is headquartered in the United States. Founded in 2003, the company has established itself as a leader in developing innovative therapeutic solutions, particularly in the fields of oncology and neurology. With a strong operational presence across North America and Europe, Mountain View Pharmaceuticals focuses on delivering high-quality, patient-centric products that address unmet medical needs. The company’s core offerings include advanced drug formulations and cutting-edge delivery systems, which distinguish them in a competitive market. Notable achievements include successful collaborations with leading research institutions and a robust pipeline of clinical trials. Mountain View Pharmaceuticals continues to solidify its market position through a commitment to research and development, aiming to improve patient outcomes and enhance the quality of life for individuals facing serious health challenges.
DitchCarbon Score
How does Mountain View Pharmaceuticals, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Mountain View Pharmaceuticals, Inc.'s score of 7 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Mountain View Pharmaceuticals, Inc.'s reported carbon emissions
In 2022, Mountain View Pharmaceuticals, Inc. reported total carbon emissions of approximately 763,800,000 kg CO2e. This figure includes 22,500,000 kg CO2e from Scope 1 emissions, 40,500,000 kg CO2e from Scope 2 emissions, and a significant 700,900,000 kg CO2e from Scope 3 emissions. The Scope 3 emissions are primarily driven by purchased goods and services, which account for about 665,000,000 kg CO2e. Comparatively, in 2021, the company’s total emissions were approximately 695,400,000 kg CO2e, with Scope 1 emissions at 23,800,000 kg CO2e and Scope 2 emissions at 43,600,000 kg CO2e. This indicates an increase in total emissions year-on-year, primarily due to the rise in Scope 3 emissions. Mountain View Pharmaceuticals has not set specific reduction targets or initiatives as part of their climate commitments, nor do they participate in recognised frameworks such as the Science Based Targets initiative (SBTi). The company has not disclosed any climate pledges or reduction initiatives, indicating a potential area for future development in their sustainability strategy. Overall, while Mountain View Pharmaceuticals, Inc. has made strides in emissions reporting, the absence of reduction targets highlights the need for a more proactive approach to climate commitments.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2020 | 2021 | 2022 | |
|---|---|---|---|
| Scope 1 | 25,200,000 | 00,000,000 | 00,000,000 |
| Scope 2 | 45,800,000 | 00,000,000 | 00,000,000 |
| Scope 3 | 610,600,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Mountain View Pharmaceuticals, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
